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AMP activated protein kinaseInsulin resistance in type 2 diabetes (T2D) is associated with intramuscular lipid (IMCL) accumulation. To
determine whether impaired lipid oxidation is involved in IMCL accumulation, we measured expression of
genes involved in mitochondrial oxidative metabolism or biogenesis, mitochondrial content and palmitate
beta-oxidation before and after palmitate overload (600 μM for 16 h), in myotubes derived from healthy
subjects and obese T2D patients. Mitochondrial gene expression, content and network were not different
between groups. Basal palmitate beta-oxidation was not affected in T2D myotubes, whereas after 16 h of
palmitate pre-treatment, T2D myotubes in contrast to control myotubes, showed an inability to increase
palmitate beta-oxidation (pb0.05). Interestingly, acetyl-CoA carboxylase (ACC) phosphorylation was
increased with a tendency for statistical signiﬁcance after palmitate pre-treatment in control myotubes
(p=0.06) but not in T2D myotubes which can explain their inability to increase palmitate beta-oxidation
after palmitate overload. To determine whether the activation of the AMP activated protein kinase (AMPK)-
ACC pathway was able to decrease lipid content in T2D myotubes, cells were treated with AICAR and
metformin. These AMPK activators had no effect on ACC and AMPK phosphorylation in T2D myotubes as well
as on lipid content, whereas AICAR, but not metformin, increased AMPK phosphorylation in control myotubes.
Interestingly, metformin treatment and mitochondrial inhibition by antimycin induced increased lipid
content in control myotubes. We conclude that T2D myotubes display an impaired capacity to respond to
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During overweight and obesity development, a redistribution of
adipose tissue occurs with increased accumulation of visceral fat. This
ectopic lipid accumulation has been shown to be related to diversemetabolic diseases including dyslipidemia, cardiovascular disease,
insulin resistance and type 2 diabetes (T2D). In healthy people,
skeletal muscle accounts ~80% of postprandial glucose disposal.
However, during T2D development, skeletal muscle becomes the
primary site of insulin resistance [1,2]. Several studies have
demonstrated a strong negative relationship between ectopic lipids
accumulation in skeletal muscle (intramyocellular lipid (IMCL)) and
whole body insulin resistance [3–5]. However, the precise mecha-
nisms leading to IMCL accumulation during T2D development are still
under investigation. During the last decade, several studies have
focused on the implication of mitochondrial dysfunction in insulin
resistance development and IMCL accumulation [6–10]. Mitochon-
drial oxidative phosphorylation was shown to be reduced in the
skeletal muscle of type 2 diabetic patients [6–8] and lean insulin-
resistant offspring of type 2 diabetic parents [9,10]. However, more
recent studies have shown that mitochondrial function is not altered
in T2D skeletal muscle when normalised for mitochondrial content
[11] or when diabetic and non-diabetic subjects are matched for body
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content in skeletal muscle of diabetic patients is an increased fatty-
acid (FA) uptake due to increased membrane expression of the major
muscle FA transporter FAT/CD36 [13].
Primary human myotubes isolated from type 2 diabetic patients
have been shown to express metabolic characteristics that approxi-
mate the in vivo phenotype of the donor subject [14–19]. This in vitro
muscle system provides an attractive model in which lipid accumu-
lation can be evaluated apart from the systemic inﬂuences of the in
vivo environment. We have recently shown in this model that an
increased membrane expression of FAT/CD36 could explain ~50% of
the increase in lipid content in myotubes derived from obese T2D
patients [20]. Thus, other mechanisms may be involved in increased
IMCL content in myotubes derived from obese T2D patients. Reduced
lipid oxidation, particularly oxidation of saturated FA [21,22], as well
as reduced citrate synthase activity [23], have been shown to be
maintained in myotubes established from obese T2D patients. More
recently, it has been shown that myotubes derived from obese T2D
patients present a decrease in intramyocellular lipid oxidation
compared to control myotubes and that this decrease in lipid
oxidation was not the result of lower mitochondrial mass [24].
However, the cause of impaired mitochondrial function per se during
T2D is not clearly understood and still under investigation.
Among the different treatments for type 2 diabetes, it is important
to note that some of them act through the same target. Indeed,
physical activity, metformin and thiazolidinediones activate AMP
activated protein kinase (AMPK). AMPK is a major metabolic sensor
which is activated by an increase in the ratio of AMP/ATP in order to
restore energy status of the cell by stimulating ATP-producing
pathways (glucose uptake, fatty acid oxidation, and mitochondrial
biogenesis) [25–27] and inhibiting ATP-consuming pathways (fatty
acid synthesis, glycogen synthesis, and protein synthesis) [28–30].
Interestingly, some studies have shown that the activation of AMPK
induces an increase in mitochondrial function and lipid oxidation
leading to decreased IMCL content [31–33]. This effect could be the
result of an increase in long-chain FA entrance and oxidation in
mitochondria due to the reduction in ACC (acetyl-CoA carboxylase)
activity, a well known target of AMPK [34,35]. Taken together these
results show that AMPK activation may be an excellent target in order
to decrease lipid content in the skeletal muscle of type 2 diabetes
patients.
In order to gain further insight into the mechanisms underlying
elevated lipid accumulation in T2D primary muscle cells, the aim of
our study was to determine whether lipid oxidation is affected in
basal condition or after palmitate overload in diabetic myotubes
compared to control myotubes and to better understand the
mechanisms leading to these defects. We also tested whether AMPK
activation could modulate lipid content in these myotubes.
2. Materials and methods
2.1. Primary human satellite cell culture
Skeletal muscle biopsy of the vastus lateralis was performed
according to the percutaneous Bergström technique after local anesthe-
sia (xylocaine) [36,37]. The experimental protocol was approved by the
local ethic committee (03/10/GESE, Montpellier, France). Informed and
written consent was obtained from all subjects after explanation of the
protocol. In the present study, biopsies were taken from four control
subjects (age: 49.2±2.7 years, bodymass index: 24.0±1.2 kg/m2)with
no familial or personal history of diabetes and from ﬁve moderately
obese type 2 diabetic patients (age: 53.4±2.4 years, body mass index:
31.5±0.6 kg/m2). Clinical characteristics of the subjectswere previously
described [21,41]. Cell culture of primary human satellite cells was
performed as previously described [20]. Cultures were maintained in a
growth medium composed of (DMEM, 10% FBS and 1% Ultroser G) andwhen myoblasts reached conﬂuence, medium was changed (growth
mediumminusUltroserG) and thedifferentiationprocess occurreduntil
fusion and terminal differentiation into contractile myotubes (8 days).
The experiments were performed on passages 2 to 4, after 8 days of
differentiation.2.2. Myotube treatments
Treatments performed on differentiated myotubes are detailed in
the ﬁgure legends and were done in triplicate for each of the
independent cell cultures. The following reagents were purchased
from Sigma-Aldrich (Saint Quentin Fallavier, France): L-Glutamine,
DMEM, antimycin A, AMP-mimetic 5-aminoimidazole-4-carboxamide-
1-β-D-ribofuranoside (AICAR), metformin and palmitate. Fetal bovine
serumwas fromHyclone (Brebières, France). Palmitatewas dissolved in
chloroform (0.6 mol/l), diluted to 600 μM in DMEM containing 10% of
FBS (differentiation medium) and added to themyotubes as previously
described [20,38].2.3. Lipid accumulation
Lipid accumulation inmyotubeswas visualized by oil red O (Sigma,
Saint-Quentin Fallavier, France) staining as previously described
[20,38,39]. Oil red O staining was carried for 1 h followed by 2 or 3
washes with distilled water. Lipid droplets were then visualized by
light microscopy. In order to quantify lipid accumulation in myotubes,
oil red O was extracted using isopropanol. The absorbance value was
measured using a spectrophotometer set at 490 nm and blanked to
untreated cells [20,38,39].2.4. Real-time RT-PCR analysis
Total RNA was isolated with Trizol (Invitrogen, Cergy-Pontoise,
France) and single-strand cDNA was synthesized from 2.5 μg of total
RNA with random hexamer primers and Superscript II (Invitrogen,
Cergy-Pontoise, France). Real-time RT-PCR reactions were carried out
with a LightCycler reaction kit (Eurogenetec, Angers, France) in a ﬁnal
volume of 20 μl containing 125 ng of reverse-transcribed total RNA,
500 nM of primers [40], 10 μl of 2× PCR mix and 0.5 μl of SYBR Green.
The reactions were carried out in capillaries in a LightCycler
instrument (Roche, Rosny-sous-bois, France) with 40 cycles. We
determined the relative amounts of the mRNAs studied by means of
the second derivative maximum method, with LightCycler analysis
software version 3.5 and 18S RNA as the invariant control for all
studies.2.5. Western blots
Cellular extracts were quantiﬁed and lysed in Laemmli buffer.
Thirty to 50 μg of total proteins were transferred to nitro-cellulose
membranes (Schleicher and Schuell, Bioscience, Dassel, Germany).
Western blots were performed as described [41]. The following
primary antibodies were used: phospho-Ser222-ACC, ACC, phospho-
Thr172-AMPK and AMPK (Cell signaling, Paris, France), non-glycosy-
lated protein component of mitochondria (Ab2, Interchim, Montlu-
con, France); and anti-α-tubulin (Sigma Saint-Quentin Fallavier,
France) was used as a loading control. The secondary antibodies
were anti-rabbit and anti-mouse antibodies coupled to horseradish
peroxidase (GE Healthcare, Orsay, France). Proteins were visualized
using an enhanced luminescent reagent (Tebu-Bio), and exposed on
ﬁlm (GE Healthcare, Orsay, France). Expression of proteins was
quantiﬁed by density analysis using ImageJ Launcher Software.
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Cellular extractswere homogenized in a solution containing: 10 mM
Tris HCl (pH 7.2), 0.1 mM EDTA, 75 mM saccharose and 225 mM
mannitol. Citrate synthase activity was measured with 0.5 mM
oxaloacetate, 0.3 mM acetyl-CoA, 0.1 mM of 5, 5’-Dithiobis 2-nitro-
benzoic acid (DTNB), 100 mMTrisHCL (pH=8.0) and0.1% Triton 100×.
Enzyme activitywasmonitored by recording the changes in absorbance
at 412 nm over 2 min at 37 °C, and normalized to protein content.
2.7. Immunoﬂuorescence
Differentiated satellite cells were ﬁxed with 4% paraformaldehyde
in PBS for 10 min, permeabilized with 0.5% triton in PBS for 2 min,
saturated with 0.5% BSA in PBS for 10 min and then incubated with
primary antibodies against a non-glycosylated protein component of
mitochondria (Ab2, Interchim, Montlucon, France). Secondary anti-
body was Alexa Fluor 596 anti-mouse (Invitrogen, Molecular Probes,
France).
2.8. Palmitate beta-oxidation
Cells were cultured in 96-well plates and differentiated as
described above. Differentiated satellite cells were exposed or not to
cold palmitate (0.6 mM) for the last 16 h of differentiation and then
exposed to differentiation medium (DMEM+10% Foetal Bovin
Serum) supplemented with 1% bovine serum albumin, 50 μM
palmitate and 9.5 μM (0,09 μCi) [1-14C]palmitate. Identical incuba-
tions were conducted on parallel plates that contained no cells.
Palmitate beta-oxidation was determined bymeasuring production of
14C-labeled acid-soluble metabolites (ASM), a measure of tricarbox-
ylic acid cycle intermediates and acetyl esters. After incubation for
30 min at 37 °C, reactions were terminated by aspiration of the media
and addition of 100 μl of HClO4 at 5% for 15 min at room temperature.
The ASM was assayed in supernatants of the acid precipitate.
Radioactivity of ASM was determined by liquid scintillation counting
by use of 4.5 ml of liquid scintillation cocktail (Optiphase “Hisafe” 3,
Perkin Elmer) in scintillation vials. For protein determination,
identical incubations were conducted on parallel plates with the
same number of cells.
2.9. Statistical analysis
Statistical analyses were performed using Statview 5.0. Data are
means±SEM. Statistical analyses were performed using Student's t
test for unpaired and paired comparison, or ANOVAwith Fisher's PLSD
post-hoc test for multiple comparisons. pb0.05 was considered to be
signiﬁcant.
3. Results
As previously shown by our team, lipid content in the presence of
palmitate is increased in myotubes derived from obese T2D patients
as compared to myotubes derived from healthy control subjects [20].
Here, we have conﬁrmed this ﬁnding (Fig. S1A and B, pb0.01).
3.1. Mitochondrial content and network are normal in T2D myotubes
We examined several mitochondrial parameters between control
and T2D myotubes in order to determine whether mitochondrial
content is decreased in T2D myotubes.
We ﬁrst measured the mRNA levels of genes involved in mitochon-
drial oxidative metabolism (citrate synthase (CS) and 3-hydroxy-acyl-
CoA-dehydrogenase (HAD)) of a gene known to mediate the transcrip-
tional control of mitochondrial biogenesis (nuclear respiratory factor 1
(NRF1)) and of a gene involved mitochondrial lipid uptake (carnitinepalmitoyltransferase 1 (CPT1)). The expression of all of these genes was
not signiﬁcantly different between control and T2D myotubes (Fig. 1A).
Wedeterminedbywesternblot theexpressionof anon-glycosylated
protein component of mitochondria (Ab2) which has been previously
used by others as a marker of mitochondria in subcellular fractions [42]
(Fig. 1B). As a second marker of mitochondrial content, we measured
the activity of citrate synthase (Fig. 1C). As shown in Fig. 1B and C, the
expression of the non-glycosylated protein component of mitochondria
was variable between subjects independently of type 2 diabetes, and
citrate synthase activity was not signiﬁcantly different between control
and T2D myotubes. Furthermore, we have performed immunoﬂuores-
cence experiments to check the speciﬁcity of the antibody used in
western blot as well as to determine whether the mitochondrial
network was different between the two groups (Fig. 1D). As shown in
Fig. 1D, mitochondria Ab-2 antibody showed a speciﬁc mitochondrial
“spaghetti”-like staining pattern in the cytoplasmof control aswell as in
T2D myotubes, without obvious differences in morphology between
groups.
Taken together, results presented in Fig. 1 show that neither
mitochondrial content nor the mitochondrial network is affected in
differentiated primary muscle cells derived from obese T2D patients.
3.2. Palmitate pre-treatment reveals mitochondrial dysfunction and an
abnormal response at the level of ACC phosphorylation in T2D
differentiated cells
A reduction in fatty acid oxidation with no difference in
mitochondrial content has been observed in T2D myotubes [24]. We
measured palmitate beta-oxidation in fully differentiated myotubes
without palmitate pre-treatment (−) or with 16 h of palmitate pre-
treatment (+, cold palmitate, 600 μM). As shown in Fig. 2A, palmitate
beta-oxidation was not signiﬁcantly different in T2D differentiated
cells compared to control cells in the basal state, but was signiﬁcantly
lower in T2Dmyotubes compared to control myotubes after palmitate
overload (pb0.05). There was a trend for an increased palmitate
oxidation after palmitate pre-treatment compared to basal condition
in control myotubes (p=0.09), but not in T2D myotubes (p=0.37).
We have next monitored ACC phosphorylation (expressed as a
ratio of phosphorylated to total protein) (Fig. 2B and C) in 4 cultures of
control and 4 cultures of T2D differentiated muscle cells. In the basal
state, ACC phosphorylation was not different between groups (Fig. 2B
and C).
We next examined the impact of palmitate pre-treatment (600 μM,
16 h) on ACC phosphorylation (Fig. 2D and E). Palmitate pre-treatment
was able to increase ACC phosphorylation in control myotubes with a
tendency of statistical signiﬁcance (p=0.06) but not in T2D myotubes
(Fig. 2D and E).
Fig. 2 shows that T2D myotubes are not able to increase palmitate
beta-oxidation and ACC phosphorylation to the same degree as
control myotubes in response to high concentrations of palmitate pre-
treatment. These results suggest that the impairment in palmitate
beta-oxidation in response to high level of palmitate pre-treatment in
T2D myotubes (Fig. 2A) could be explained by an abnormal response
to palmitate at the level of ACC phosphorylation (Fig. 2D and E).
3.3. AICAR or metformin treatments are not able to decrease lipid
content in T2D myotubes
To test whether AMPK activation was able to decrease lipid
content in T2D myotubes, fully differentiated myotubes were treated
with 2 different AMPK activators: AICAR (5-aminoimidazole-4-
carboxamide-β-D-ribofuranoside) and metformin (Fig. 3). AICAR
treatment for 16 h showed a signiﬁcantly increased AMPK phosphor-
ylation only in control myotubes (pb0.05) but not in T2D myotubes,
due to a greater variability in the response to AICAR treatment in our
T2D cells (Fig. 3A and B). However, the phosphorylation of ACC was
Fig. 1.Mitochondrial gene expression, content and network in control and T2Dmyotubes. A. Expression of genes encoding proteins involved in mitochondrial oxidative metabolism
(citrate synthase, CS and 3-hydroxy-acyl-CoA-dehydrogenase, HAD), in transcriptional control of mitochondrial biogenesis (nuclear respiratory factor 1, NRF1) and in lipid
metabolism (carnitine palmitoyltransferase 1, CPT1) was evaluated by quantitative real-time RT-PCR in control (n=4) and T2D differentiated satellite cells (n=4). Each value
indicates the amount of mRNA expressed relative to 18S RNA. Each experiment was performed in triplicate for each of the 8 independent cell cultures. Data are presented as means
±SEM normalized to mRNA level in control myotubes. B. Representative western blot analysis of a non glycosylated protein component of mitochondria (Ab2) expression in
myotubes established from control and T2Dmyotubes. α-Tubulin was used as a loading control. C. Citrate synthase activity was determined in control (n=3) and T2D differentiated
satellite cells (n=3) under basal conditions and expressed relative to protein content. Experiments were performed in duplicate for each of the 6 independent cell cultures. Data are
means±SEM. D. Representative immunoﬂuorescence microscopy of control and T2Dmyotubes after 8 days of differentiation, incubated with an antibody against a non glycosylated
protein component of mitochondria (Ab2) visualized using a monoclonal secondary antibody conjugated to Alexa 546. Scale bar represents 30 μm.
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and C). Metformin treatment for 16 h did not increase either AMPK or
ACC phosphorylation in control and T2D myotubes (Fig. 3A, B and C).
As a consequence, no decrease in lipid accumulation was observed in
T2D myotubes after metformin and AICAR treatments (Fig. 3D, left
panel). AICAR treatment also had no effect on lipid content in control
myotubes (Fig. 3D, left panel). Surprisingly, long term metformin
treatment induced a signiﬁcant increase in lipid content in control
myotubes but not in myotubes from T2D patients (Fig. 3D, right
panel).3.4. Mitochondrial inhibition alters lipid content in control myotubes
AICAR activates AMPK by increasing the intracellular pool of ZMP,
an AMPK analogue (for review see [43]). Metformin activates AMPK
indirectly by inhibiting complex I of the respiratory chain [44,45].
Thus we sought to examine the effect of antimycin A, a mitochondrial
inhibitor (complex III), before challenging cells with a high concen-
tration of palmitate (600 μM for 16 h) in order to evaluate if the
metformin effect on lipid accumulation could be attributable to
mitochondrial inhibition. As shown in Fig. 4A and B, after treatment of
the cells with antimycin A, palmitate-induced lipid accumulation in
control myotubes was signiﬁcantly increased by 22% (pb0.05).
Interestingly, no increase in lipid content was found in T2D myotubesafter antimycin A treatment which is in accordance with the results
shown in Fig. 4 after metformin treatment.
Fig. 4 shows that mitochondrial inhibition is sufﬁcient to increase
lipid content in control myotubes to the same level as in T2D
myotubes.
4. Discussion
Mitochondrial involvement in intramuscular lipid accumulation
and T2D development has been widely studied over the last 10 years.
Numerous studies have shown a mitochondrial dysfunction in
skeletal muscle of T2D patients [6–8] as well as in muscle from
persons at risk for developing T2D [9,10]. However, these results have
been refuted in more recent studies showing that mitochondrial
functionwas not altered in T2D skeletal muscle after normalization by
mitochondria content [11] or when T2D and control subjects were
matched for obesity [12]. Thus, the involvement of mitochondrial
dysfunction in T2D is still under investigation. In the present study, we
have shown that baseline palmitate oxidation and mitochondrial
content were similar between primary human satellite cells derived
from healthy control subjects and moderately obese T2D patients. A
defect in palmitate beta-oxidation was only revealed when T2D
myotubes were challenged with high concentrations of palmitate, and
this impaired response to palmitate overload could be the result of a
lack of inhibition of ACC activity by palmitate. Thus a mitochondrial
Fig. 2. Effect of palmitate pre-treatment on palmitate beta-oxidation and phosphorylated acetyl-CoA carboxylase expression in control and T2D myotubes. A. Basal palmitate
beta-oxidation and palmitate beta-oxidation after 16 h of cold palmitate pre-treatment (600 μM) in control (n=3) and T2D differentiated satellite cells (n=3) expressed
relative to protein content. Experiments were performed in triplicate for each of the 6 independent cell cultures. Data are means±SEM. *pb0.05, T2D cells versus control cells.
B. Representative western blot analysis of P-ACC in differentiated satellite cells established from 4 control subjects and 4 type 2 diabetic (T2D) patients in the basal state (no
palmitate pre-treatment). ACC protein expression was used as a loading control. C. Quantiﬁcation by density analysis of western blot shown in (A). Data are means ± SEM.
D. Representative western blot analysis of P-ACC in differentiated satellite cells established from 4 control subjects and 4 type 2 diabetic (T2D) patients with (+) or without (−)
palmitate pre-treatment (600 μM for 16 h). ACC protein expression was used as a loading control. E. Quantiﬁcation by density analysis of P-ACC and ACC expression in myotubes
established from control subjects (n=4) and T2D patients (n=4) with (+) or without (−) palmitate pre-treatment (600 μM for 16 h). Data are means±SEM. p=0.06,
palmitate-treated differentiated satellite cells versus untreated cells.
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saturated fatty acid overload. This result is in accordancewith another
study showing that myotubes from patients with a history of type 2
diabetes were unable to adapt to a hyperglycaemic–hyperinsulinaemic
challenge [46]. Thus, it seems that response to nutrient challenge is
impaired in T2D myotubes.
In the present study, we used primary muscle cells in culture to
study mitochondrial fatty acid oxidation apart from the systemic
inﬂuences of the in vivo environment. Interestingly, under basal
conditions (no palmitate pre-treatment), no evidence for differential
expression of genes involved in mitochondrial oxidative metabolism
or in genes involved in mitochondrial biogenesis was found between
myotubes derived from lean healthy subjects and obese type 2 diabetic
patients, conﬁrming results previously described [47]. Furthermore,
we found no differences in mitochondrial content (estimated by
citrate synthase activity or expression of amitochondrial protein) or in
the mitochondrial network between the two populations of cells.These results differ from previous published ﬁndings showing an
intrinsic defect in citrate synthase activity [23] but are in accordance
with a recent study [24].
Under basal conditions, we found no signiﬁcant difference in
palmitate beta-oxidation in cells derived from obese type 2 diabetic
patients compared to those derived from control subjects. This result
may be due to a lack of power in consequence of the small n size.
However, only one out of 3 T2D myotubes show smaller beta-
oxidation values than the control cells. Interestingly, after palmitate
pre-treatment for 16 h, palmitate beta-oxidation was signiﬁcantly
decreased in T2D myotubes compared to control cells. Palmitate pre-
treatment also revealed a greater increase in lipid content in T2D
myotubes as compared to control cells, whereas no difference in lipid
accumulation was found between the two groups of myotubes in
basal conditions (not shown). Thus, control myotubes were able to
increase palmitate beta-oxidation after palmitate pre-treatment
allowing an onlymoderate lipid accumulation whereas T2Dmyotubes
Fig. 3. Effect of AMPK activation on lipid accumulation in control and T2Dmyotubes. A. Representative western blot analysis of P-ACC and P-AMPK in differentiated satellite cells
established from a control subjects and a type 2 diabetic (T2D) patients. AMPK and ACC protein expressions were used as loading controls. B. Quantiﬁcation by density analysis of
P-AMPK (left panel) and P-ACC (right panel) in myotubes with (+) or without (−) AICAR (500 μM) or metformin (2 mM) treatment for 16 h, from 4 cultures established from
control subjects and 5 cultures established from type 2 diabetic patients (T2D). Data are presented normalized to AMPK and ACC expression, respectively. Data are shown as
mean±SEM. *pb0.05, basal versus AICAR for control cells. C. Quantiﬁcation of lipid content in control (n=3) and T2D differentiated satellite cells (n=3–4) with (+) or without
(−) AICAR (500 μM, left panel) or metformin (2 mM, right panel) treatment (30 min) followed by palmitate treatment (600 μM for 16 h). Data are means±SEM. Each point was
assayed in triplicate for each of the 7 independent cell cultures. *pb0.05, T2D cells versus control cells. #pb0.05, metformin and palmitate treatment versus palmitate alone.
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level of palmitate beta-oxidation (compared Fig. 2A with Fig. 2B)
leading to greater lipid accumulation. The stimulation of fatty acid
beta-oxidation by high concentrations of palmitate in control
myotubes is in accordance with another study [48]. Moreover, direct
inhibition of the electron transport chain by antimycin A and
metformin was able to increase palmitate-induced lipid accumulation
in control myotubes showing that mitochondrial inhibition can in fact
lead to increased lipid content in control myotubes. In contrast, in
satellite cells derived from obese T2D patients, neither antimycin A
nor metformin treatment lead to an increase in lipid content in T2D
myotubes indicating that mitochondrial function was already defec-
tive in T2D myotubes or that the lipid accumulation capacity in T2D
myotubes was already at its maximum without these treatments.
To obtain mechanistic insights into the modiﬁed response to
palmitate pre-treatment in T2D myotubes, we monitored changes in
P-ACC. Active (dephosphorylated) ACC inhibits fatty acid oxidation by
increasing the availability of malonyl-CoA which, in turn, inhibits
carnitine palmitoyl transferase 1 (CPT1) and the entrance of long-
chain fatty acid in mitochondria. Phosphorylation of ACC inhibits its
activity leading to increased fatty acid uptake by mitochondria and,
subsequently, increased fatty acid oxidation [49,50]. In the basal state,
no difference in P-ACC or ACC expression was observed between
groups. After palmitate pre-treatment, the phosphorylation of ACCtends to be increased in control myotubes which is in accordancewith
the increase in palmitate beta-oxidation is those myotubes. Interest-
ingly, in T2Dmyotubes, nomodiﬁcation of the phosphorylation of ACC
was observed after palmitate overload. Thus a lack of inhibition of ACC
could explain why palmitate beta-oxidation was not increase in T2D
myotubes in response to palmitate overload. Interestingly lack of a
signiﬁcant increase in AMPK phosphorylation was also found in T2D
myotubes following AICAR treatment. This result, taken together with
the absence of ACC inhibition by palmitate treatment in T2D
myotubes suggests that T2D myotubes display a defective response
to different stimuli at the level of the AMPK-ACC pathway. These
preliminary but really intriguing results need further investigation to
better understand the mechanisms leading to this defect in T2D
myotubes. Unfortunately, due to the inability of T2D myotubes to
activate the AMPK-ACC pathway, we were not able to reduce lipid
content in T2D myotubes. Other experiments are necessary to
determine whether AMPK is a good target in order to decrease lipid
content in T2D myotubes.
Somemethodological aspects of the study should be acknowledged.
In thepresent study,we focusedon response topalmitate overload since
it iswell known that insulin resistance development in response to high
FA level is the consequenceof high saturated FA level (i.e. palmitate) and
not to high unsaturated FA level (i.e. oleate) [51–54]. We acknowledge
that the use of 600 μM of palmitate is not physiological since, in vivo,
Fig. 4. Effect of mitochondrial inhibition on lipid accumulation in control and T2D myotubes. A. Representative phase contrast microscopy of control and T2Dmyotubes after 16 h of
palmitate (600 μM) treatment with (+) or without (−) previous treatment with antimycin A (1 μM for 30 min). Scale represents 30 μm. B. Quantiﬁcation of lipid content in control
(n=4) and T2D differentiated satellite cells (n=5)with (+) or without (−) antimycin A stimulation (1 μM for 30 min) followed by palmitate treatment (600 μM for 16 h). Data are
means±SEM. Each point was assayed in triplicate for each of the 9 independent cell cultures. **pb0.01 palmitate-treated T2D cells versus control cells; #pb0.05 antimycin+
palmitate-treated control versus palmitate-treated control cells.
429M. Kitzmann et al. / Biochimica et Biophysica Acta 1812 (2011) 423–430circulating free FA are a mix of saturated and unsaturated FA. The best
experiment would be to use a cocktail of FA (i.e. oleate+palmitate)
since it has been shown that the adverse effect of palmitate on cellular
functions can be rescued with the addition of oleate [53,54]. However,
our results are in accordancewith a recent study using only oleate as FA
supply [24].
In summary, this study shows that skeletal muscle cells derived
from moderately obese T2D patients exhibited decreased palmitate
beta-oxidation and increased lipid accumulation in response to
palmitate overload, possibly due to a palmitate-induced inhibition
of ACC. In contrast, control myotubes responded to fatty acid overload
with an increase in palmitate oxidation, and less lipid accumulation;
this response did not reﬂect an inability of control myotubes to
accumulate lipid as demonstrated by the antimycin A and metformin
experiments. Studies are needed to evaluate whether the inhibition of
ACC phosphorylation in control myotubes is able to reproduce the
diabetic phenotype (i.e. decreased palmitate beta-oxidation and
increasedmyotube lipid content) and to evaluate whether an increase
in ACC phosphorylation in T2D myotubes is able to increase palmitate
beta-oxidation and decrease lipid accumulation.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbadis.2010.12.007.
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